Close
Back to mobile site

Pre-Open Stock Movers 04/20: AlloVir, I-Mab Biopharma Gain; Netflix Plunges (more...)

April 20, 2022 9:23 AM EDT

Pre-Open Stock Movers:

Netflix (NASDAQ: NFLX) 28% LOWER; Q1 global streaming subscribers fell 200k versus an expected gain of 2.5 million. Q1 EPS was $3.53, versus the consensus of $2.90. Revenue was $7.87 billion versus the consensus estimate of $7.93 billion. Netflix sees Q2 2022 EPS of $3.00, versus the consensus of $3.01. Netflix sees Q2 2022 revenue of $8.05 billion, versus the consensus of $8.21 billion. The company sees Q2 global streaming paid net additions of -2 million, versus the consensus of 2.4 million.

AlloVir (NASDAQ: ALVR) 25% HIGHER; FDA Grants RMAT Designation for Posoleucel

I-Mab Biopharma (NASDAQ: IMAB) 17% HIGHER; is exploring options including a sale amid takeover interest, Bloomberg reported.

Roku, Inc. (NASDAQ: ROKU) 7% LOWER; falls on Netflix's results, which could be an ominous sign for Roku's results.

The Walt Disney Company (NYSE: DIS) 5% LOWER; falls on Netflix's results, which could be ominous for Disney+ numbers.

Teva (NYSE: TEVA) 4% LOWER; The company and MedinCell announced that the FDA has issued a Complete Response Letter regarding the New Drug Application (NDA) for TV-46000/mdc-IRM (risperidone extended-release injectable suspension for subcutaneous use) for the treatment of schizophrenia

Spotify (NYSE: SPOT) 4% LOWER; falls on Netflix's results.

Stride Inc. (NYSE: LRN) 4% HIGHER; reported Q3 EPS of $1.02, versus the consensus of $0.84. Revenue was $421.7 million versus the consensus estimate of $411.12 million. Stride Inc. sees FY2022 revenue of $1.645-1.66 billion, versus the consensus of $1.63 billion

Anthem (NYSE: ANTM) 3% HIGHER; posted Q1 EPS of $8.25, versus the consensus of $7.81. Revenue was $37.9 billion versus the consensus of $37.42 billion. Anthem sees FY2022 EPS of $28.40, versus the consensus of $28.48

IBM (NYSE: IBM) 2% HIGHER; Q1 EPS was reported at $1.40, $0.02 better than the analyst estimate of $1.38. Revenue was $14.2 billion versus the consensus estimate of $13.85 billion. The company sees revenue growth for the year at the high end of its model.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Special Reports

Related Entities

Pre-Open Losers, Pre-Open Winners, Pre Market Movers, FDA